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Introduction
In 2015 there were 183,529 new cases of prostate cancer reported and 28,848 men died from
prostate cancer in the United States, according to the Center for Disease Control (CDC). Prostate
cancer is the most prevalent cancer in US men, affecting 99 out of every 100,000 with the next
highest being lung cancer effecting 66 per 100,000 men. According to the CDC, the rate of new
prostate cancer diagnoses has declined from 169 per 100,000 men in 1999 to the current 99 per
100,000 in 2015. This data is affected by the growing and aging population in the US each year.
Looking at the number of new cases of prostate cancer beginning in 1999, there were 196,349
cases reported, which is slightly higher than the number in 2015, but not proportional to the
change in rate. Prostate cancer rates double every 5 years after the age of 50 and are highest
amongst men between 65 and 75 at a rate of 580 per 100,000 in this age group.1
Since prostate cancer prevalence is so high, multiple treatment modalities have been
developed, with a curative goal. The most common prostate cancer treatments include radical
prostatectomy (RP), which is simple removal of the prostate; and external beam radiation
therapy (EBRT), which is destruction of the cancer cells via direct focused beams of radiation
aimed at the tumor from outside the body.2 Other treatment modalities for prostate cancer
exist, but these two particular modalities are the subject of this literary review. Both treatments
have different cancer related mortality outcomes; and both have varying side effects, which can
affect the patient’s quality of life. These side effects most commonly include urinary incontinence
and erectile dysfunction, but may also include rectal pain, dysuria, fatigue, depression and
secondary malignancy.3‐4 There have been many studies identifying the efficacy and patient
mortality rates associated with each treatment modality. However, there have been conflicting
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findings, and they do not incorporate the effects on quality of life. The aim of this literary review
is to examine men over 60 years old with localized prostate cancer; then determine the effect of
external beam radiation on quality of life and mortality compared to radical prostatectomy. The
hope is to paint a clearer picture, so that a single treatment modality can be the primary choice
for these patients in the future.
Prostate Cancer Mortality After Treatment
One of the most valuable statistics, when assessing treatment modalities, is the mortality
rate after treatment with each type. More specifically, the mortality rates of patients with
localized prostate cancer treated with radical prostatectomy, external beam radiation therapy or
another modality. There have been numerous primary, population‐based and retrospective
studies identifying mortality rates of these treatments, but there has been a large variation in
these results. It is important to note that there is a variable application with each modality.
Regarding radical prostatectomy, there are different approaches surgeons can take, including
robotically assisted procedures. External radiation will have different doses of radiation, and the
precision at which the radiation is delivered represents a variable. The aim is to measure each of
these modalities in their entirety, regardless of their approach or variables in implementation.
Radical prostatectomy was most often compared to EBRT, since these are the two leading
treatments for localized prostate cancer. A study assessing 10‐year survival rates of men with
localized prostate cancer that underwent RP and EBRT found the 10‐year survival probability was
75.3% after RP and 36.7% after EBRT. In a multivariate Cox regression model, EBRT was
associated with a 3.9‐fold higher chance of mortality in the entire study group.5 This study was
limited by the inclusion of all levels of Gleason scores, including the poorly differentiated. The
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study also included individuals who were already at lower probability for 10‐year survival, due to
comorbidities. This study demonstrated a wide difference in survival rates between EBRT and
RP, but other population‐based studies did not yield similar results.
A study was performed with the goal to assess the survival among men with localized
prostate cancer who received RP or EBRT, but also included patients treated with brachytherapy.
Patients with localized prostate cancer were included in the study and were treated with RP,
EBRT and brachytherapy. The results of this study demonstrated a 10‐year overall survival of
88.9% (RP), 82.6% (EBRT) and 81.7% (BT).6 The prostate cancer specific mortality was found to
be lowest amongst patients who received RP. In conclusion, this study found that EBRT was
associated with a significantly increased risk of prostate cancer specific mortality compared to
radical prostatectomy. BT was also associated with a significantly decreased overall survival
compared to RP. The difference in 10‐year survival probability in this paper did not vary as much
as the findings from the prior study,5 but still demonstrated that RP was associated with a
statistically significant improvement in overall and cancer specific mortality.
The findings that RP has improved mortality outcomes compared to other modalities was
echoed in a similar article. In a population based analysis, 68,665 patients with localized prostate
cancer were treated with RP or EBRT and their cancer caused mortality was assessed. The results
of this analysis demonstrated that the 10‐year cancer specific mortality rates of EBRT was over
2‐fold higher than RP. In patients aged 65‐69 years old the 10‐year cancer specific mortality rate
for EBRT was 2.7% higher than RP.7 The results showed radiotherapy was associated with
statistically significant less favorable cancer‐specific mortality amongst all age ranges and
prostate cancer grades. The author concluded that patients undergoing prostatectomy fare
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substantially better than those treated with radiation therapy, especially for patients with high‐
risk prostate cancer. The benefit of this study, is the sample group was divided into age ranges;
cancer risks; and adjusted for comorbidities, which could influence the overall survival rates.
These findings again state that radical prostatectomy was associated with better mortality
outcomes compared to radiation therapy.
The tumor risk of metastasis or local spread is a variable that some studies addressed and
could potentially have an impact on the survival rates of patients who underwent different
treatment modalities. Even if the prostate cancer is localized, there is still potential for spread,
which can change the recommendation for treatment. A study was performed to analyze the
long‐term survival of high‐risk prostate cancer patients who were treated with RP vs EBRT. Their
population‐based analysis identified 1,238 patients who were treated with RP, and 609 treated
with EBRT between 1988‐2004. The inclusion criteria was a PSA > 20ng/mL; Gleason score 8‐10;
and tumor stage of > T3.8 At this tumor stage the cancer is still localized, but has potentially
spread to the surrounding tissue. The results of this study demonstrated that the 10‐year cancer
specific survival was 92% for the RP group and 88% for the EBRT group.8 The risk of all‐cause
mortality was found to be statistically significantly greater in the EBRT group compared to the RP
group.8 The author felt continued investigation into the variable impact of prostate cancer
therapies on quality‐of‐life and non‐cancer mortality was important to aid in identifying the
optimal treatment for these patients.
The population‐based studies, above all, demonstrated that radical prostatectomy was
associated with high 10‐year cancer specific survival outcomes, or lower cancer specific mortality
rates compared to external beam radiation. These results were consistent with the findings of
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eight other population‐based studies and retrospective analyses studies, which were identified
throughout the literature review. However, the impact on quality‐of‐life is a major deciding factor
for patients undergoing prostate cancer treatment and is the second variable this article will
attempt to identify.
Treatment Impact on Quality‐of‐Life
Patients undergoing treatment for prostate cancer are most often concerned with the
impact each treatment modality has on their quality of life. There are several symptoms that are
associated with each type of treatment, and some symptoms are shared by multiple treatments.
There is an importance of educating patients on these side effects of treatment, as this may guide
their selection, but the aim is to identify the treatment with least impact on quality of life.
However, analyzing the symptoms is difficult, as well as predicting which patients may become
symptomatic. The most common and most irritating symptoms were identified in hopes of
determining a treatment plan associated with the least impact on quality of life.
A study performed to evaluate the quality of life outcomes used data obtained for 4 years
after treatment for local prostate cancer in 475 patients. This was performed by interviewing
patients and administering a questionnaire where they identified their most concerning
symptoms. Urinary incontinence was the most commonly reported symptom and occurred in
307 patients receiving RP and 78 patients receiving EBRT.9 Sexual dysfunction affected all
treatment groups in the study, but radical prostatectomy demonstrated a higher chance of
regaining baseline function compared to EBRT.9 Bowel dysfunction was observed to occur with
more frequency in patients receiving EBRT than RP. The strengths of this study were the
documentation of the patient’s pre‐treatment baseline, so they could assess any subsequent
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decline in function or new symptoms and their possible return to baseline. This analysis was
limited, because there were no statistical analytical tools that could be performed to qualify the
effects on quality of life. Patients who had cancer recurrence were not separated from the study,
and this recurrence can negatively impact the patients’ well‐being.
In an attempt to mitigate some of the common side effects patients experience after
treatment, there have been new developments in how these procedures are performed,
specifically radical prostatectomy.

Nerve sparing radical prostatectomy procedures have

increased in prevalence in recent years, creating a decrease in urinary symptoms after treatment.
In a prospective study, 1201 patients and 625 spouses were evaluated to measure treatment
outcomes and patient satisfaction. Five hundred sixty‐one of these patients underwent nerve
sparing radical prostatectomy; 41 underwent non‐nerve sparing procedures; and 202 patients
received EBRT. Health‐related quality of life was evaluated before, during, and after treatments
in domains of sexual function, urinary incontinence, urinary irritation or obstruction, urinary
function, bowel or rectal function and vitality of hormonal control.10 It was found that all groups
reported their sexual quality of life was affected, but patients in the nerve‐sparing RP group had
better recovery of sexual quality of life compared to non‐nerve sparing RP. However, 44% of
men in the RP group reported erectile dysfunction compared to 22% in the EBRT group. Urinary
incontinence peaked at two months after surgery and then gradually returned to baseline for
most patients, and their baseline scores of urinary irritation and obstruction improved after RP.
The EBRT groups’ post‐surgical urinary symptoms had resolved after 12 months and were
improved over baseline after 24 months.10 Comparing urinary symptoms between RP and EBRT
groups, shows 7% and 11% of patients reported worse urinary symptoms from baseline after 2
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years, respectively. The bowel dysfunction was the next most significant domain and indicted
that 9% of EBRT patients reported rectal urgency, pain, fecal incontinence, or hematochezia,
while there were no substantive change in bowel function reported in the RP group.10 The
limitations of this study is the number of coexisting illnesses and severity of cancer was highest
in patients in the radiotherapy group and smallest in the RP group, which could potentially
increase the negative perception on satisfaction of EBRT compared to RP.

This study

demonstrates that barring its limitations, RP is associated with less urinary, sexual dysfunction,
and bowel symptoms compared to EBRT groups, as well as decreased recovery time of
symptoms.
Decisional regret, after prostate cancer treatment, is directly correlated to post‐
treatment urinary symptoms and overall patient satisfaction.11 In a retrospective study, a self‐
administered questionnaire was sent to prostate cancer patients in France. Of the completed
questionnaires, 110 patients had received RP and 28 received EBRT.

The results of the

questionnaire found urinary incontinence was reported by 34.5% of patients treated with RP and
17.8% of patients treated with radiotherapy only. Questions regarding decisional regret were
also asked, and it was found that the main reason for decisional regret was due to incomplete
information about prostate cancer. Thirty‐four percent of patients contributed the regret to
urinary symptoms from treatment that they were not warned about.11 This study demonstrates
the importance of appropriate patient education, when deciding their preferred course of
treatment, especially in the era of patient‐centered care.
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Conclusion
In analyzing the effects of radical prostatectomy and external beam radiation therapy on
prostate cancer specific mortality, almost all literature reviewed demonstrated that RP had
higher probabilities of survival and lower probabilities of cancer specific mortality compared to
EBRT. Quality of life outcomes were difficult to statistically evaluate, but the studies that were
reviewed demonstrated a higher percentage of post‐treatment symptomatic complaints with
EBRT compared to RP.

These two treatment modalities did share complaints of urinary

incontinence and urinary irritation, but these symptoms improved and/or returned to baseline
significantly sooner in the RP group compared to the EBRT group. Rectal symptoms including
pain, fecal incontinence, and hematochezia were only experience by the EBRT group. Due to the
improved mortality rates and decreased severity and duration of post‐treatment symptoms,
radical prostatectomy is seemingly a better first‐line treatment modality compared to external
beam radiation therapy. Given that prostate cancer is the most prevalent cancer amongst US
men, there is sufficient data to suggest that radical prostatectomy should be considered for first
line treatment in individuals with localized prostate cancer. However, current studies are
underway assessing the use of improved radiation therapy techniques in treatment of localized
prostate cancer but this data is still not fully collected. The goal of a health care provider is to
help patients make a proper decision, but that is based on the most current information, and that
information is dynamic, fluid, evolving and requires further research.

9

References
1. “Prostate Cancer.” Centers for Disease Control and Prevention, Centers for Disease Control
and Prevention, 7 Nov. 2018, www.cdc.gov/cancer/prostate/index.htm.
2. Froehner M. Re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al.
Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External‐Beam
Radiation Therapy, or Brachytherapy in Men Without Comorbidity. Eur Urol
2013;64:372–8. European Urology. 2014;65(3):372‐378.
doi:10.1016/j.eururo.2013.11.035.
3. Goineau A, Campion L, d'Aillières B, et al. Comprehensive geriatric assessment and quality
of life after localized prostate cancer radiotherapy in elderly patients. PLoS ONE.
2018;13(4):e0194173. Accessed Jun 16, 2018. doi: 10.1371/journal.pone.0194173.
4. Shin DW, Park HS, Lee SH, et al. Health‐related quality of life, perceived social support, and
depression in disease‐free survivors who underwent curative surgery only for prostate,
kidney and bladder cancer: Comparison among survivors and with the general
population. Cancer Res Treat. 2018. Accessed Jun 16, 2018. doi: 10.4143/crt.2018.053.
5. Jeldres C, Suardi N, Perrotte P, et al. Survival after radical prostatectomy and radiotherapy
for prostate cancer: a population‐based study. Canadian Urological Association Journal.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645889/. Published February 2009.
Accessed October 19, 2018.
6. Kibel AS, Ciezki JP, Klein EA, et al. Survival among men with clinically localized prostate
cancer treated with radical prostatectomy or radiation therapy in the prostate specific
antigen era. J Urol. 2012;187(4):1259‐1265. Accessed Jun 16, 2018. doi:
10.1016/j.juro.2011.11.084.
7. Abdollah F, Schmitges J, Sun M, et al. Comparison of mortality outcomes after radical
prostatectomy versus radiotherapy in patients with localized prostate cancer: A
population‐based analysis. Int J Urol. 2012;19(9):836‐844. Accessed Jun 16, 2018. doi:
10.1111/j.1442‐2042.2012.03052.x.
8. Boorjian SA, Karnes RJ, Viterbo R, et al. Long‐term survival after radical prostatectomy
versus external‐beam radiotherapy for patients with high‐risk prostate cancer. Cancer.

10

2011;117(13):2883‐2891. https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.25900.
doi: 10.1002/cncr.25900.
9. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48‐month
quality‐of‐life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst.
2009;101(12):888‐892. Accessed Jun 16, 2018. doi: 10.1093/jnci/djp114.
10. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among
prostate‐cancer survivors. N Engl J Med. 2008;358(12):1250‐1261. Accessed Jun 16,
2018. doi: 10.1056/NEJMoa074311.
11. Albkri A, Girier D, Mestre A, Costa P, Droupy S, Chevrot A. Urinary incontinence, patient
satisfaction, and decisional regret after prostate cancer treatment: A french national
study. Urol Int. 2018;100(1):50‐56. Accessed Jun 16, 2018. doi: 10.1159/000484616
12. Abdollah F, Sun M, Thuret R, et al. A competing‐risks analysis of survival after alternative
treatment modalities for prostate cancer patients: 1988‐2006. Eur Urol. 2011;59(1):88‐
95. Accessed Jun 16, 2018. doi: 10.1016/j.eururo.2010.10.003.
13. Barocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or
observation for localized prostate cancer and patient‐reported outcomes after 3
years. JAMA. 2017;317(11):1126‐1140. Accessed Jun 16, 2018. doi:
10.1001/jama.2017.1704.
14. Boorjian SA, Eastham JA, Graefen M, et al. A critical analysis of the long‐term impact of
radical prostatectomy on cancer control and function outcomes. Eur Urol.
2012;61(4):664‐675. Accessed Jun 16, 2018. doi: 10.1016/j.eururo.2011.11.053.
15. Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk‐adjusted mortality
outcomes after primary surgery, radiotherapy, or androgen‐deprivation therapy for
localized prostate cancer. Cancer. 2010;116(22):5226‐5234.
https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.25456. doi: 10.1002/cncr.25456
16. Froehner, Michael, M.D.|Koch, Rainer, Ph.D.|Litz, Rainer J., M.D.|Wirth, Manfred P., M.D.
Re: Guzzo et al.: Prediction of mortality after radical prostatectomy by charlson
comorbidity index. (urology 2010;76:553‐557). Urology.
2010;76(6):1522. https://www.clinicalkey.es/playcontent/1‐s2.0‐S0090429510016560.
doi: 10.1016/j.urology.2010.07.524.

11

17. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate‐specific antigen free
survival outcomes for patients with low, intermediate and high risk prostate cancer
treatment by radical therapy. results from the prostate cancer results study group. BJU
Int. 2012;109 Suppl 1:22‐29. Accessed Jun 16, 2018. doi: 10.1111/j.1464‐
410X.2011.10827.x.
18. Hamdy FC, Donovan JL, Lane JA, et al. 10‐year outcomes after monitoring, surgery, or
radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415‐1424.
Accessed Jun 16, 2018. doi: 10.1056/NEJMoa1606220.
19. Hashine K, Kakuda T, Iuchi S, Hosokawa T, Ninomiya I. Prospective longitudinal outcomes of
quality of life after laparoscopic radical prostatectomy compared with retropubic radical
prostatectomy. Health Qual Life Outcomes. 2018;16(1):7. Accessed Jun 16, 2018. doi:
10.1186/s12955‐017‐0835‐1.
20. Jack Hadley, K Robin Yabroff, Michael J Barrett, David F Penson, Christopher S Saigal, Arnold
L Potosky. Comparative effectiveness of prostate cancer treatments: Evaluating
statistical adjustments for confounding in observational data. Journal of the National
Cancer Institute. 2010;102(23):1780‐
1793. http://www.ncbi.nlm.nih.gov/pubmed/20944078. doi: 10.1093/jnci/djq393
21. Kishan AU, Cook RR, Ciezki JP, et al. Radical prostatectomy, external beam radiotherapy, or
external beam radiotherapy with brachytherapy boost and disease progression and
mortality in patients with gleason score 9‐10 prostate cancer. JAMA. 2018;319(9):896‐
905. Accessed Jun 16, 2018. doi: 10.1001/jama.2018.0587.
22. Ladjevardi S, Berglund A, Varenhorst E, Bratt O, Widmark A, Sandblom G. Treatment with
curative intent and survival in men with high‐risk prostate cancer. A population‐based
study of 11 380 men with serum PSA level 20‐100 ng/mL. BJU Int. 2013;111(3):381‐388.
Accessed Jun 16, 2018. doi: 10.1111/j.1464‐410X.2012.11320.x.
23. . Lemanska A, Dearnaley DP, Jena R, Sydes MR, Faithfull S. Older age, early symptoms and
physical function are associated with the severity of late symptom clusters for men
undergoing radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol). 2018;30(6):334‐
345. Accessed Jun 16, 2018. doi: 10.1016/j.clon.2018.01.016.

12

